Resource Summary Report

Generated by dkNET on Sep 11, 2026

NCI-H196

RRID:CVCL_1509
Type: Cell Line

Proper Citation

RRID:CVCL_1509

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1509

Proper Citation: RRID:CVCL_1509

Description: Cell line NCI-H196 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung sarcomatoid carcinoma

Defining Citation: PMID:2985257, PMID:2986243, PMID:8806092, PMID:8806103, PMID:11030152, PMID:17426248, PMID:20215515, PMID:22460905, PMID:25485619, PMID:25877200, PMID:25960936, PMID:25984343, PMID:26589293, PMID:27247353, PMID:27397505, PMID:28766886, PMID:30894373, PMID:31068700, PMID:31803961, PMID:31978347, PMID:32586373, PMID:35839778, PMID:38180245

Comments: Caution: Originally classified as originating from a lung small cell carcinoma, but is reclassified as a lung sarcomatoid carcinoma based on a number of criteria (PubMed=38180245)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H196

Synonyms: H196, H-196, NCIH196

Cross References: BTO:BTO_0003027, CLO:CLO_0008033, EFO:EFO_0006668, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5823, BioSample:SAMN03471881, BioSample:SAMN10988217,

cancercelllines:CVCL_1509, Cell_Model_Passport:SIDM00761, CLS:300390, Cosmic:852003, Cosmic:953990, Cosmic:1995546, Cosmic-CLP:1240186, DepMap:ACH-000752, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240186, GEO:GSM169451, GEO:GSM170732, GEO:GSM170733, GEO:GSM784210, GEO:GSM827362, GEO:GSM844633, GEO:GSM845541, GEO:GSM887392, GEO:GSM888470, GEO:GSM986170, GEO:GSM1670201, GEO:GSM1887889, GEO:GSM1887969, KCLB:90196, LiGeA:CCLE_482, LINCS_LDP:LCL-1813, PharmacoDB:NCIH196_1051_2019, PRIDE:PXD011896, PRIDE:PXD030304, Progenetix:CVCL_1509, Wikidata:Q54907886

ID: CVCL_1509

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260905T181242+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H196.

Warning: Discontinued: KCLB; 90196
Caution: Originally classified as originating from a lung small cell carcinoma, but is reclassified as a lung sarcomatoid carcinoma based on a number of criteria (PubMed=38180245)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Campisi M, et al. (2026) Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer. Cancer cell, 44(4), 858.

Ahmad T, et al. (2026) KDM7B-mediated demethylation of RNF113A regulates small cell lung cancer sensitivity to alkylation damage. bioRxiv : the preprint server for biology.

Coussens NP, et al. (2025) Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids. SLAS discovery : advancing life sciences R & D, 33, 100230.

De Rosa C, et al. (2025) DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. iScience, 28(3), 111943.

Flor AC, et al. (2025) Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites. Redox biology, 80, 103504.

Fnu T, et al. (2025) Sympathetic Neurons Promote Small Cell Lung Cancer through the ? 2-Adrenergic Receptor. Cancer discovery, 15(3), 616.

Iñañez A, et al. (2025) The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. International journal of molecular sciences, 26(3).

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, OF1.

Chakraborty S, et al. (2024) Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Cell reports. Medicine, 5(12), 101852.

Dexheimer TS, et al. (2023) Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. Cancer research communications, 3(8), 1648.

Lukinovi? V, et al. (2022) SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk. Cancer discovery, 12(9), 2158.

Taniguchi H, et al. (2022) WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell reports, 39(7), 110814.

Thomas A, et al. (2021) Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer cell, 39(4), 566.

Schenk MW, et al. (2021) Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. Nature communications, 12(1), 6652.